Barthélémy David, Belmonte Elodie, Pilla Laurie Di, Bardel Claire, Duport Eve, Gautier Veronique, Payen Léa
Institut of Pharmaceutical and Biological Sciences of Lyon, Claude Bernard Lyon I, 69373 Lyon, France.
Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Réseau Francophone de Pharmacogénétique (RNPGx), 69495 Pierre-Bénite, France.
J Pers Med. 2023 Nov 27;13(12):1655. doi: 10.3390/jpm13121655.
Pharmacogenetics (PGx) aims to determine genetic signatures that can be used in clinical settings to individualize treatment for each patient, including anti-cancer drugs, anti-psychotics, and painkillers. Taken together, a better understanding of the impacts of genetic variants on the corresponding protein function or expression permits the prediction of the pharmacological response: responders, non-responders, and those with adverse drug reactions (ADRs).
This work provides a comparison between innovative long-read sequencing (LRS) and short-read sequencing (SRS) techniques.
The gene panel captured using PacBio HiFi sequencing was tested on thirteen clinical samples on GENTYANE's platform. SRS, using a comprehensive pharmacogenetics panel, was performed in routine settings at the Civil Hospitals of Lyon. We focused on complex regions analysis, including copy number variations (CNVs), structural variants, repeated regions, and phasing-haplotyping for three key pharmacogenes: , and .
Variants and the corresponding expected star (*) alleles were reported. Although only 38.4% concordance was found for haplotype determination and 61.5% for diplotype, this did not affect the metabolism scoring. A better accuracy of LRS was obtained for the detection of the haplotype in the presence of the duplicated wild-type form. A total concordance was performed for TA repeat detection. Direct phasing using the LRS approach allowed us to correct certain profiles.
Combining an optimized variant-calling pipeline and with direct phasing analysis, LRS is a robust technique for PGx analysis that can minimize the risk of mis-haplotyping.
药物遗传学(PGx)旨在确定可在临床环境中用于为每位患者个体化治疗的基因特征,包括抗癌药物、抗精神病药物和止痛药。总体而言,更好地了解基因变异对相应蛋白质功能或表达的影响有助于预测药理反应:反应者、无反应者以及有药物不良反应(ADR)者。
本研究比较了创新的长读长测序(LRS)和短读长测序(SRS)技术。
在GENTYANE平台上对13个临床样本测试了使用PacBio HiFi测序捕获的基因panel。在里昂市民医院的常规环境中使用综合药物遗传学panel进行SRS。我们专注于复杂区域分析,包括三个关键药物基因的拷贝数变异(CNV)、结构变异、重复区域和定相单倍型: 、 和 。
报告了变异和相应的预期星号(*)等位基因。尽管单倍型测定的一致性仅为38.4%,双倍型为61.5%,但这并未影响代谢评分。在存在重复野生型 形式的情况下,LRS检测 单倍型的准确性更高。TA重复检测实现了完全一致。使用LRS方法的直接定相使我们能够校正某些 图谱。
结合优化的变异检测流程和直接定相分析,LRS是一种用于PGx分析的强大技术,可将错误单倍型分型的风险降至最低。